185 completed, 52 recruiting, 33 active not recruiting, 33 terminated. 129 Phase 2, 62 Phase 3, 58 Phase 1, 53 Not applicable, 9 Phase 4.
Follow X-Linked Intellectual Disability: new trials by email Literature Review of X-Linked Intellectual Disability trials Research Report on X-Linked Intellectual Disability
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome NTI164, Placebo - RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome | Phase 2 / Phase 3 | Not yet recruiting | Fenix Innovation Group | 40 | 2027-07-01 | 2026-09-09 |
| IT and IV Lentiviral Gene Therapy for X-ALD Intrathecal and intravenous LV gene therapy - X-linked Adrenoleukodystrophy | Not applicable | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-01 | 2026-11-02 |
| A Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 in Adult Male Participants With Fragile X Syndrome S247240 Low dose, S247240 Middle dose, S247240 High dose - Fragile X Syndrome (FXS) | Phase 2 | Not yet recruiting | Institut de Recherches Internationales Servier (I.R.I.S.) | 100 | 2027-01-25 | 2026-11-12 |
| A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS Codabakalner, Placebo - Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD) | Phase 2 / Phase 3 | Not yet recruiting | Spinogenix | 120 | 2026-12-01 | 2026-10-09 |
| Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome SRX246, Placebo - Aggressive Behavior in Fragile X Syndome | Phase 2 | Not yet recruiting | Azevan Pharmaceuticals | 80 | 2026-12-01 | 2026-10-30 |
| Single Session Support for Parents of Children With Neurodevelopmental Disabilities Struggling With Anxious Avoidance EMPOWER-ND - Neurodevelopmental Disorders, Autism Spectrum Disorder (ASD) | Not applicable | Not yet recruiting | Boston University Charles River Campus | 50 | 2026-11-01 | 2026-10-27 |
| To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome Bionetide, Placebo - Rett Syndrome | Phase 3 | Recruiting | Biomed Industries, Inc. | 210 | 2026-09-30 | 2026-03-27 |
| A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome Rett-T, Placebo - Rett Syndrome | Phase 2 | Recruiting | Holland Bloorview Kids Rehabilitation Hospital | 35 | 2026-08-24 | 2026-09-02 |
| NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease Droxidopa Oral Product, Placebo Control - Menkes Disease | Phase 1 / Phase 2 | Recruiting | Stephen G. Kaler | 6 | 2026-08-10 | 2026-10-05 |
| Adapting a Psychosocial Support Intervention for the Rett Syndrome Community Those who have patients prescribed Daybue, Caregiver Speaks + Daybue - Rett Syndrome, Family Caregivers | Not applicable | Not yet recruiting | Colorado State University | 60 | 2026-08-01 | 2026-07-28 |
| The Neurocognitive Bases of Trust in Intellectual Disability Confidence adjustment assessment, clinical assessment, Cognitive assessment - Down Syndrome (Trisomy 21), Fragile X Syndrome (FXS) | Recruiting | Hospices Civils de Lyon | 112 | 2026-07-17 | 2026-08-05 | |
| A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome fenfluramine hydrochloride, Placebo - Rett Syndrome | Phase 3 | Recruiting | UCB BIOSCIENCES, Inc. | 200 | 2026-07-14 | 2026-11-02 |
| Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal Disorders Outpatient Clinic of the Clinical Unit of Endocrinology at the Modena University Hospital (AOU Modena) Cushing s Syndrome, Cushing Disease | Recruiting | Azienda Ospedaliero-Universitaria di Modena | 2000 | 2026-07-09 | 2026-11-09 | |
| Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome CTH120, CTH120 placebo hard capsules - Fragile X Syndrome (FXS), Fragile X Syndrome | Phase 2 | Recruiting | Connecta Therapeutics, S.L. | 30 | 2026-05-21 | 2026-07-17 |
| Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome TSHA-102 - Rett Syndrome | Phase 3 | Active not recruiting | Taysha Gene Therapies, Inc. | 4 | 2026-05-08 | 2026-08-19 |
| Optical Imaging in X-linked Disorders. Clinical assessment, Parental questionnaires, Cognitive assessment - Fragile X Syndrome (FXS), Creatine Transporter Deficiency | Not applicable | Recruiting | Hospices Civils de Lyon | 118 | 2026-03-30 | 2026-05-15 |
| Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome Vorinostat (SAHA), Placebo - Rett Syndrome | Phase 1 | Recruiting | Unravel Biosciences, Inc. | 15 | 2026-03-15 | 2026-09-17 |
| Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD) | Recruiting | Healing Hope International | 100 | 2026-03-01 | 2026-03-25 | |
| RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) RGX-121-3102 - MPS II, Hunter Syndrome (MPS II) | Phase 3 | Active not recruiting | REGENXBIO Inc. | 2 | 2025-11-25 | 2026-06-04 |
| Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379 - Fragile X Syndrome | Phase 2 | Recruiting | Mirum Pharmaceuticals, Inc. | 60 | 2025-11-22 | 2026-09-29 |
Showing 20 of 373. Sign in to see all of them.
Fragile X Syndrome (115) · Rett Syndrome (95) · Mucopolysaccharidosis II (77) · Adrenoleukodystrophy (63) · Sudden Infant Death (34) · Mucopolysaccharidosis I (24) · Intellectual Disability (22) · Leukodystrophy, Metachromatic (21) · Autism Spectrum Disorder (20) · Autistic Disorder (18) · Mucopolysaccharidoses (18) · Genetic Diseases, Inborn (17) · Genetic Diseases, X-Linked (17) · Leukodystrophy, Globoid Cell (17) · Lysosomal Storage Diseases (17)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (371) · Heredodegenerative Disorders, Nervous System (363) · Nervous System Diseases (362) · Neurologic Manifestations (361) · Neurobehavioral Manifestations (360) · Genetic Diseases, Inborn (356) · Genetic Diseases, X-Linked (356) · Intellectual Disability (350) · Nutritional and Metabolic Diseases (173) · Metabolic Diseases (159) · Metabolism, Inborn Errors (150) · Congenital Abnormalities (129) · Chromosome Disorders (116) · Sex Chromosome Disorders (114)
idursulfase (14) · trofinetide (8) · mavoglurant (6) · Alemtuzumab (5) · Metformin (5) · arbaclofen placarbil (5) · BPN14770 (4) · Dextromethorphan (4) · Donepezil (4) · Injections (4) · Lovastatin (4) · Melphalan (4) · Minocycline (4) · Stem Cell Transplantation (4) · gaboxadol (4)
Shire (15) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (9) · Seaside Therapeutics, Inc. (9) · Children's Hospital Medical Center, Cincinnati (8) · Stanford University (8) · JCR Pharmaceuticals Co., Ltd. (7) · Masonic Cancer Center, University of Minnesota (7) · Novartis Pharmaceuticals (6) · REGENXBIO Inc. (6) · University of California, Davis (6) · Assistance Publique - Hôpitaux de Paris (5) · Genetix Biotherapeutics Inc. (5) · Green Cross Corporation (5) · Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (5) · Rett Syndrome Research Trust (5)
United States (236) · United Kingdom (46) · France (40) · Italy (37) · Spain (37) · Canada (32) · Germany (27) · Australia (24) · Netherlands (18) · Brazil (16) · Argentina (11) · China (10) · Israel (9) · Belgium (8) · Mexico (8)
Elizabeth Berry-Kravis, MD, PhD (5) · Paul Orchard, MD (5) · Alan Percy, MD (4) · Joanne Kurtzberg, MD (4) · Randi J Hagerman, MD (4) · Allan L Reiss (3) · Bryan King, MD, PhD (3) · Craig Erickson, MD (3) · Craig Erikson, MD (3) · Elizabeth Berry-Kravis, MD (3) · James McCracken, MD (3) · Jeremy Veenstra-VanderWeele, MD (3)
PMID 37460385, PMID 33395098, PMID 38363467, PMID 39383458, PMID 19772971, PMID 21586746, PMID 23035069, PMID 24399845, PMID 25071871, PMID 25283752, PMID 25801175, PMID 26764156, PMID 26855682, PMID 35568815, PMID 35794169, PMID 35961250, PMID 37915038, PMID 38723617, PMID 39383459, PMID 10331611, PMID 10517635, PMID 10595921, PMID 10797443, PMID 11231629, PMID 11241498, PMID 11399225, PMID 12103288, PMID 15368082, PMID 15492353, PMID 15521982, PMID 15551335, PMID 15923132, PMID 16278898, PMID 16411192, PMID 17482283, PMID 18203205, PMID 18256395, PMID 18337588, PMID 18752978, PMID 19194885, PMID 19833552, PMID 19892975, PMID 19914908, PMID 20032810, PMID 20231667, PMID 20497190, PMID 20652413, PMID 20937127, PMID 21059347, PMID 21104896
2023 (4), 2019 (3), 2009 (2), 2014 (2), 2018 (2), 2025 (2), K23HD109375 (2), U54HD061222 (2), U54NS065768 (2), 2004 (1), 2015 (1), K23MH077554 (1), K23NS087151 (1), P01HD024448 (1), R01AG076678 (1)